title: 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.
authors.forename: Valentina
authors.initials: V
authors.lastname: Ambrosini
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Cristina
authors.initials: C
authors.lastname: Nanni
authors.forename: Adil
authors.initials: A
authors.lastname: Al-Nahhas
authors.forename: Stefano
authors.initials: S
authors.lastname: Fanti
mesh_terms: D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D006801:Humans; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine; C513399:gallium Ga 68 dotatate